Wave Life Sciences
On March 26, 2025, Wave Life Sciences (WVE) announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
FORWARD-53 Trial demonstrates sustained and industry-leading exon . . .
This content is for paid subscribers.
Impacting News
March 28, 2025